| 肺癌患者围化疗期血清CYFRA21-1、NSE和CA125水平变化的价值探讨 |
| |
| 引用本文： | 张 健,邵丽华,张征宇.肺癌患者围化疗期血清CYFRA21-1、NSE和CA125水平变化的价值探讨[J].现代肿瘤医学,2019,0(3):403-406. |
| |
| 作者姓名： | 张 健 邵丽华 张征宇 |
| |
| 作者单位： | 丹东市中医院肿瘤科，辽宁 丹东 118000 |
| |
| 摘 要： | 目的:探讨肺癌患者围化疗期血清细胞角蛋白19片段（CYFRA21-1）、神经元特异性烯醇化酶（NSE）和糖类抗原125（CA125）水平变化的价值。方法:选自我院于2015年12月至2017年12月期间收治的97例肺癌患者作为研究组；另选自我院于2015年12月至2017年12月期间收治的80例肺部良性病变患者作为对照组。采集患者外周静脉血，分离血清，采用电化学发光法检测CYFRA21-1、NSE和CA125含量。比较两组患者血清CYFRA21-1、NSE和CA125含量，不同临床分期化疗前后CYFRA21-1、NSE和CA125含量变化，不同疗效化疗前后CYFRA21-1、NSE和CA125含量变化。结果:研究组血清CYFRA21-1、NSE和CA125的含量高于对照组，且差异有统计学意义（P<0.05）。I-Ⅱ期和Ⅲ-Ⅳ期患者化疗后血清CYFRA21-1、NSE和CA125的含量较化疗前明显下降（P<0.05）；Ⅲ-Ⅳ期患者化疗前和化疗后血清CYFRA21-1、NSE和CA125的含量高于同期I-Ⅱ期患者（P<0.05）。CR+PR和SD+PD患者化疗后血清CYFRA21-1、NSE和CA125含量均较化疗前明显下降（P<0.05）；SD+PD患者化疗前和化疗后血清CYFRA21-1、NSE和CA125含量均高于同期CR+PR患者（P<0.05）。结论:肺癌患者血清CYFRA21-1、NSE和CA125含量明显升高，且随着病情加重含量升高越明显，化疗后其含量明显下降，有助于临床的进一步研究。
|
| 关 键 词： | 肺癌 围化疗期 细胞角蛋白19片段 神经元特异性烯醇化酶 糖类抗原125 |
The study on the value of the changes of serum CYFRA21-1，NSE and CA125 levels in patients with lung cancer during the perioperative period of chemotherapy |
| |
| Zhang Jian,Shao Lihua,Zhang Zhengyu.The study on the value of the changes of serum CYFRA21-1，NSE and CA125 levels in patients with lung cancer during the perioperative period of chemotherapy[J].Journal of Modern Oncology,2019,0(3):403-406. |
| |
| Authors: | Zhang Jian Shao Lihua Zhang Zhengyu |
| |
| Affiliation: | Oncology Department，Dandong Hospital of Traditional Chinese Medicine，Liaoning Dandong 118000，China. |
| |
| Abstract: | Objective:To investigate the value of serum CYFRA21-1，neuron specific enolase（NSE) and carbohydrate antigen 125（CA125) level in lung cancer patients during chemotherapy.Methods:97 cases of lung cancer received chemotherapy in our hospital from December 2015 to December 2017 were selected as the research group.80 cases of benign pulmonary lesions were selected as control group from December 2015 to December 2017.The peripheral venous blood was collected.The serum was isolated and the content of CYFRA21-1，NSE and CA125 were detected by electrochemiluminescence.The contents of serum CYFRA21-1，NSE and CA125 in two groups were compared.The levels of CYFRA21-1，NSE and CA125 in different clinical stages before and after chemotherapy were compared.The contents of CYFRA21-1，NSE and CA125 were compared before and after chemotherapy.Results:The content of serum CYFRA21-1，NSE and CA125 in the research group was higher than that of the control group，and there was a statistically significant difference（P<0.05).The serum levels of CYFRA21-1，NSE and CA125 in I-Ⅱ and Ⅲ-Ⅳ stage after chemotherapy were significantly lower than that before chemotherapy（P<0.05).In the Ⅲ-Ⅳ stage，serum levels of CYFRA21-1，NSE and CA125 were higher than that Ⅰ-Ⅱ stage before and after chemotherapy（P<0.05).The serum levels of CYFRA21-1，NSE and CA125 in CR+PR and SD+PD after chemotherapy were significantly lower than that before chemotherapy（P<0.05).Serum levels of CYFRA21-1，NSE and CA125 in SD+PD were higher than that in CR+PR before and after chemotherapy(P<0.05).Conclusion:The levels of serum CYFRA21-1，NSE and CA125 in patients with lung cancer increased significantly，and the level of them decreased after chemotherapy. |
| |
| Keywords: | lung cancer peri-chemotherapeutic period cytokeratin-19-fragment neuron specific enolase carbohydrate antigen 125 |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
